Grifols, S.A. (GRFS) News
Filter GRFS News Items
GRFS News Results
|Loading, please wait...|
GRFS News Highlights
- 500 - Internal server error
- Over the past 16 days, the trend for GRFS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about GRFS are PD, VIVO and BIO.
Latest GRFS News From Around the Web
Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.
Kepler Capital Stick to Their Hold Rating for Grifols SA
Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and innovative diagnostic solutions, today announced it will provide the Korean Red Cross (KRC) with its industry-leading Procleix Panther System running nucleic acid testing (NAT) technology to help ensure the safety of South Korea's blood supply.
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis.
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal BMC Biology. The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies. “A major goal in oncology is to find strategies that enhance the infiltration of immune T cells in the tumor to improve efficacy of therapies, while reducing resistance and toxic effects,” said Erica Stone, Ph.D., vice president of Oncology at GigaGen and auth...
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.
Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 9, 2021. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2020.
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results.
Blood Plasma Derivatives Market Size to Grow at a Remarkable Pace in the Coming Years : Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG
The insight Partners Research has recently added a concise research on the Global Blood Plasma Derivatives Market – Industry Trends and Forecast to 2027. A reliable Global Blood Plasma Derivatives Market report contains market data that can be relatively essential
BARCELONA, Spain , March 22, 2021 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ: GRFS ), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today announced its first-ever installation in North America of the DG Reader Net semi-automated analyzer, used to facilitate pre-transfusion blood type compatibility testing. This platform, the newest addition to the company's scalable solutions for blood banks, is now running at ThedaCare Medical Center-Wild Rose in Wisconsin . Many small, specialized laboratories like ThedaCare Medical Center-Wild Rose work hard to offer high quality service in pre-transfusion testing with limited semi-automated solutions available to them, resulting in manual testing that coul...
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million.